Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Cancer-Savvy New CMO Eager to Extend Astellas’ Oncology Portfolio, Bag Speedy Approval
October 28, 2022
- Takeda Files SC Immunoglobulin for Immune Disorders in Japan
October 27, 2022
- Sanofi Seeks Dupixent’s Pediatric Dosage for Eczema in Japan
October 27, 2022
- Astellas Bags Option Rights to 2 Taysha Gene Therapy Programs
October 26, 2022
- Toho Picked as Single Wholesaler for LEO Pharma’s Dovonex
October 26, 2022
- Daiichi Sankyo’s FLT3 Inhibitor Gets FDA’s Priority Review for 1st Line AML
October 26, 2022
- Chugai Logs Bumper Earnings in January-September on New Products, Exports to Roche
October 25, 2022
- Bayer Launches Xarelto Tablets 2.5 mg for PAD as Single-Channel Product
October 25, 2022
- LEO Pharma to Take Over Dovonex Distribution, Set Up Solo Sales Regime in Japan
October 25, 2022
- GSK Seeks Japan Approval of RSV Vaccine
October 24, 2022
- Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO
October 24, 2022
- Approval by January Unlikely for SanBio’s Lead Cell Therapy as Production Review Stalls
October 21, 2022
- Sunovion to Divest US Market Rights of 2 Drugs to Lupin for US$75 Million
October 21, 2022
- Kyowa Kirin Assigns Bone Metabolism Specialists to Promote Crysvita in Japan
October 20, 2022
- Bayer to Halt Sale of PAH Med Ventavis in Japan over Nebulizer Supply Issue
October 20, 2022
- MSD Started Work to Develop Easier-to-Swallow Form of Lagevrio: Exec
October 20, 2022
- Sumitomo Aiming to Take the Lead in Developing Universal Flu Vaccines
October 19, 2022
- Chugai’s Integrated Drug Discovery Research Center Completed in Yokohama
October 19, 2022
- Kyowa Kirin Files Intas-Licensed Mitomycin for Cancer Use in Japan
October 19, 2022
- Bayer to Distribute Xarelto Tablets 2.5 mg via Single Wholesaler
October 18, 2022
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…